1020657-43-5

Basic information

• Product Name: N,O3'-dibenzoylgeMcitabine
• Synonyms: N,O3'-dibenzoylgeMcitabine;N-Benzoyl-2'-deoxy-2',2'-difluorocytidine 3'-Benzoate
• CAS NO: 1020657-43-5
• Molecular Formula: C₂₃H₁₉F₂N₃O₆
• Molecular Weight: 471.41
• Mol File: 1020657-43-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• CAS DataBase Reference: N,O3'-dibenzoylgeMcitabine(CAS DataBase Reference)
• NIST Chemistry Reference: N,O3'-dibenzoylgeMcitabine(1020657-43-5)
• EPA Substance Registry System: N,O3'-dibenzoylgeMcitabine(1020657-43-5)

Safety Data

• Hazardous Substances Data: 1020657-43-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N,O3'-dibenzoylgeMcitabine is used as an intermediate in the synthesis of Gemcitabine metabolites for the development of anticancer drugs. Gemcitabine is a nucleoside analog that has been widely used in the treatment of various types of cancer, including pancreatic, breast, ovarian, and non-small cell lung cancer. N,O3'-dibenzoylgeMcitabine's role as an intermediate allows for the production of more effective and targeted cancer therapies.
Used in Drug Development:
N,O3'-dibenzoylgeMcitabine is used as a starting material for the development of novel anticancer agents. Its unique structure and properties make it a valuable component in the design and synthesis of new drugs with improved pharmacological profiles. Researchers can use this compound to explore innovative approaches to cancer treatment, potentially leading to the discovery of more effective and less toxic therapies.

Upstream product

• 1421929-71-6 C₃₀H₂₉F₂N₃O₆ 
• 98-88-4 benzoyl chloride 
• 1151528-36-7 4-amino-1-((2R,4R,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3,3-difluoro-4-hydroxytetrahydrofuran-2-yl)pyrimidin-2(1H)-one 
• 122111-03-9 gemcitabine hydrochloride 
• 1151528-37-8 C₂₉H₃₃F₂N₃O₆Si 
• 95058-81-4 gemcitabine 

Downstream Products

• 1151528-38-9 C₃₀H₂₅F₂N₃O₈S 
• 1151529-15-5 C₂₃H₁₉F₂N₃O₇ 
• 1151528-70-9 C₁₆H₁₈F₂N₄O₄ 
• 1535165-98-0 C₂₃H₁₈F₂N₆O₅ 
• 1535165-99-1 C₂₃H₂₀F₂N₄O₅ 
• 1535166-07-4 C₁₇H₁₆F₃N₅O₃ 
• 1535166-09-6 C₁₈H₁₉F₅N₄O₃ 
• 1535166-11-0 C₂₃H₂₇F₃N₆O₃ 
• 1535166-12-1 C₂₃H₂₅F₃N₆O₃ 
• 1151528-53-8 ((2R,3R,5R)-5-(4-amino-2-oxopyrimidine-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methyl-4-methylbenzenesulfonate 
• 1535166-01-8 C₃₁H₂₄F₃N₅O₅ 
• 1535166-02-9 C₂₈H₂₅F₂N₅O₆ 
• 1535166-03-0 C₃₂H₂₇F₅N₄O₅ 
• 1535166-04-1 C₂₉H₂₃F₅N₄O₆ 

Relevant articles and documents

SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS

The present invention relates to salts of triphosphate phosphoramidates which are useful in the treatment of cancer.

Efficient synthesis of gemcitabine 5′-O-triphosphate using gemcitabine 5′-O-phosphoramidate as an intermediate

A new efficient approach for the synthesis of gemcitabine triphosphate has been developed. The method is based on the ring-opening reaction of 2-cyanoethoxy-2-oxo-1,3,2-oxathiaphospholane with protected gemcitabine in the presence of DBU. Subsequent treatment of gemcitabine monophosphate with DCC in the presence of ammonia provides gemcitabine 5′-O-phosphoramidate. Finally, this compound, on reaction with pyrophosphate, furnishes gemcitabine 5′-triphosphate in 50% yield. Georg Thieme Verlag Stuttgart. New York.

Syntheses of 5′-amino-2′,5′-dideoxy-2′,2′- difluorocytidine derivatives as novel anticancer nucleoside analogs

A novel class of 5′-amino-2′,5′-dideoxy-2′, 2′-difluorocytidine derivatives has been synthesized in order to identify anticancer nucleoside analogs. Several synthetic routes were devised and implemented which relied upon either SN2 displacement

The identification of novel 5′-amino gemcitabine analogs as potent RRM1 inhibitors

The ribonucleotide reductase (RNR) enzyme is a heteromer of RRM1 and RRM2 subunits. The active enzyme catalyzes de novo reduction of ribonucleotides to generate deoxyribonucleotides (dNTPs), which are required for DNA replication and DNA repair processes.

NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits